(旧版)科学的根拠に基づく糖尿病診療ガイドライン 改訂第2版

 
12.糖尿病に合併した肥満


文献

1) 吉池信男,西 信雄,松島松翠,伊藤千賀子,池田義雄,樫原英俊,吉永英世,小倉 浩,小峰慎吾,佐藤祐造,佐藤則之,佐々木陽,藤岡滋典,奥 淳治,雨宮禎子,坂田利家,井上修二.Body Mass Indexに基づく肥満の程度と糖尿病,高血圧,高脂血症の危険因子との関連 多施設共同研究による疫学的検討.肥満研究.2000;6(1):4-17. レベル3
2) Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102-10. レベル4
3) Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab. 2000;2(2):105-12. レベル2
4) Eriksson J, Lindström J, Valle T, Aunola S, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Lauhkonen M, Lehto P, Lehtonen A, Louheranta A, Mannelin M, Martikkala V, Rastas M, Sundvall J, Turpeinen A, Viljanen T, Uusitupa M, Tuomilehto J. Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia. 1999;42(7):793-801. レベル2
5) Chow CC, Ko GT, Tsang LW, Yeung VT, Chan JC, Cockram CS. Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors. Diabetes Care. 1997;20(7):1122-7. レベル2
6) Smith DE, Heckemeyer CM, Kratt PP, Mason DA. Motivational interviewing to improve adherence to a behavioral weight-control program for older obese women with NIDDM. A pilot study. Diabetes Care. 1997;20(1):52-4. レベル2
7) Yki-Järvinen H, Ryysy L, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S, Salo S, Seppälä P, Tulokas T, Viikari J, Taskinen MR. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997;82(12):4037-43. レベル2
8) United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. Ann Intern Med. 1998;128(3):165-75. レベル2
9) Avilés-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;131(3):182-8. レベル2
10) 熊原雄一,熊谷 朗,五島雄一郎,鎮目和夫,内藤周幸,大西利夫.食欲抑制薬Mazindolの肥満症に対する臨床評価 多施設二重盲検法による検討.臨床評価.1985;13(2):461-515. レベル2
11) Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683-9. レベル3
12) Kawamoto R, Tomita H, Oka Y, Kodama A. Metabolic syndrome as a predictor of ischemic stroke in elderly persons. Intern Med. 2005;44(9):922-7. レベル4


【参考文献】
a) 松澤佑次,井上修二,池田義雄,坂田利家,齋藤 康,佐藤祐造,白井厚治,大野 誠,宮崎 滋,徳永勝人,深川光司,山之内国男,中村 正.新しい肥満の判定と肥満症の診断基準.肥満研究.2000;6(1):18-28.
b) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97.
c) Metabolic syndrome Criteria Study Group. Definition and criteria for metabolic syndrome. J Jpn Soc Intern Med. 2005;94:188-203.


 
ページトップへ

ガイドライン解説

close-ico
カテゴリで探す
五十音で探す

診療ガイドライン検索

close-ico
カテゴリで探す
五十音で探す